Programmed delivery of cyclopeptide RA-V and antisense oligonucleotides for combination therapy on hypoxic tumors and for therapeutic self-monitoring

2020 ◽  
Vol 8 (1) ◽  
pp. 256-265 ◽  
Author(s):  
Yongrong Yao ◽  
Li Feng ◽  
Zhe Wang ◽  
Huachao Chen ◽  
Ninghua Tan
Keyword(s):  
Combination Therapy ◽  
Antisense Oligonucleotides ◽  
Ph Sensitive ◽  
Therapeutic Monitoring ◽  
Caspase 8 ◽  
Self Monitoring ◽  
Selective Therapy

A pH-sensitive chemosensitization nanosystem (RA/RX Liposome) for highly selective therapy against hypoxic tumors and achieving precise therapeutic monitoring with the light-up fluorescence of the caspase-8 probe.

pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma

Biomaterials ◽  
2013 ◽  
Vol 34 (29) ◽  
pp. 7181-7190 ◽  
Author(s):  
Yinsong Wang ◽  
Hongli Chen ◽  
Yuanyuan Liu ◽  
Jing Wu ◽  
Ping Zhou ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Combination Therapy ◽  
Ph Sensitive ◽  
Combretastatin A4

Smart pH-Sensitive and Temporal-Controlled Polymeric Micelles for Effective Combination Therapy of Doxorubicin and Disulfiram

ACS Nano ◽  
2013 ◽  
Vol 7 (7) ◽  
pp. 5858-5869 ◽  
Author(s):  
Xiaopin Duan ◽  
Jisheng Xiao ◽  
Qi Yin ◽  
Zhiwen Zhang ◽  
Haijun Yu ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Polymeric Micelles ◽  
Ph Sensitive ◽  
Effective Combination

Delivery of antisense oligonucleotides by means of pH-sensitive liposomes

1997 ◽  
Vol 48 (2-3) ◽  
pp. 179-184 ◽  
Author(s):  
Monica Cristina De Oliveira ◽  
Elias Fattal ◽  
Catherine Ropert ◽  
Claude Malvy ◽  
Patrick Couvreur
Keyword(s):  
Antisense Oligonucleotides ◽  
Ph Sensitive

scholarly journals Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signalling

2003 ◽  
Vol 376 (1) ◽  
pp. 253-260 ◽  
Author(s):  
Pachiyappan KAMARAJAN ◽  
Nian-Kang SUN ◽  
Chuck C.-K. CHAO
Keyword(s):  
Cell Surface ◽  
Hela Cell ◽  
Cell Lines ◽  
Antisense Oligonucleotides ◽  
Cross Resistance ◽  
Caspase 8 ◽  
Cervix Carcinoma ◽  
Hela Cell Lines ◽  
Induced Apoptosis ◽  
Resistant Cells

Cisplatin-selected cervix carcinoma HeLa cell lines induced less apoptosis, and weaker activation by cisplatin or Fas-activating antibody, of mitochondrial-associated caspase-9 and death receptor-mediated caspase-8 than did parental cells. Furthermore, less DISC (death-inducing signalling complex) was formed in cisplatin-selected cell lines than in parental cells. Ac-IETD-CHO (acetyl-Ile-Glu-Thr-Asp-aldehyde), which has a certain preference for inhibiting caspase-8, or Fas-antagonistic antibody, significantly inhibited cisplatin-induced apoptosis in both parental and cisplatin-selected HeLa cell lines. These results imply that cell-surface death signalling is inducible by cisplatin; that reduction of this pathway is associated with drug resistance, and that cisplatin-selected cells acquire cross-resistance to cell-surface death signalling. Sequential up-regulation of FLIP (FLICE-like inhibitory protein), but not Bcl-2, Bcl-xL or inhibitors of apoptosis protein (IAPs), was observed in resistant cells but not in parental cells. The inhibition of FLIP by FLIP antisense oligonucleotides promotes cisplatin and Fas-antibody-induced apoptosis. However, the modulation of apoptosis by FLIP antisense oligonucleotides in resistant cells is greater than that in parental cells. The presented data reveal that the up-regulation of FLIP may contribute to the suppression of apoptosis and thereby change cells that are resistant to cisplatin and Fas-mediated death signals. The results also show that cancer cells that have undergone long-term chemotherapy and become chemoresistant may change the FLIP level, becoming cross-resistant to death factors such as Fas.

scholarly journals Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Yumin Zhang ◽  
Cuihong Yang ◽  
Weiwei Wang ◽  
Jinjian Liu ◽  
Qiang Liu ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Ph Sensitive

scholarly journals Multifunctional Cargo-Free Nanomedicine for Cancer Therapy

2018 ◽  
Vol 19 (10) ◽  
pp. 2963 ◽  
Author(s):  
Ying Wang ◽  
Pengfei Yang ◽  
Xinrui Zhao ◽  
Di Gao ◽  
Na Sun ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Cancer Therapy ◽  
Drug Release ◽  
Combination Therapy ◽  
Cancer Treatment ◽  
Clinical Applications ◽  
Self Monitoring ◽  
Promising Strategy ◽  
Carrier Free ◽  
Future Challenges

Nanocarriers encapsulating multiple chemotherapeutics are a promising strategy to achieve combinational chemotherapy for cancer therapy; however, they generally use exotic new carriers without therapeutic effect, which usually suffer from carrier-related toxicity issues, as well as having to pass extensive clinical trials to be drug excipients before any clinical applications. Cargo-free nanomedicines, which are fabricated by drugs themselves without new excipients and possess nanoscale characteristics to realize favorable pharmacokinetics and intracellular delivery, have been rapidly developed and drawn much attention to cancer treatment. Herein, we discuss recent advances of cargo-free nanomedicines for cancer treatment. After a brief introduction to the major types of carrier-free nanomedicine, some representative applications of these cargo-free nanomedicines are discussed, including combination therapy, immunotherapy, as well as self-monitoring of drug release. More importantly, this review draws a brief conclusion and discusses the future challenges of cargo-free nanomedicines from our perspective.

pH-Sensitive Liposomes: An Intelligent System for the Delivery of Antisense Oligonucleotides

1997 ◽  
Vol 7 (1) ◽  
pp. 1-18 ◽  
Author(s):  
Patrick Couvreu ◽  
Elias Fattal ◽  
Claude Malvy ◽  
Catherine Dubernet
Keyword(s):  
Antisense Oligonucleotides ◽  
Intelligent System ◽  
Ph Sensitive
Sign in / Sign up

Export Citation Format

Share Document